Healthcare / Medical DevicesShenzhen
$7.93
-0.22 (-2.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $16.1M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-16.0%
↓Gross Margin
40.6%
↓Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-12.9%
FCF CAGR
-19.5%
FCF margin
2.0%
FCF / Net income
-0.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $807.1M · net income $-246.0M · FCF $16.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $807.1M | $807.1M | $977.2M | $1.11B | $1.22B |
| Net Income | $-246.0M | $-246.0M | $65.2M | $159.2M | $261.8M |
| EBITDA | $-218.8M | $-218.8M | $153.6M | $220.4M | $333.1M |
| EPS | -0.90 | -0.90 | 0.24 | 0.59 | 0.95 |
| Gross Margin | 40.6% | 40.6% | 51.7% | 51.0% | 52.0% |
| Operating Margin | -10.8% | -10.8% | 7.2% | 11.7% | 22.0% |
| Net Margin | -30.5% | -30.5% | 6.7% | 14.3% | 21.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.29 | 0.29 | 0.27 | 0.17 | 0.18 |
| Current Ratio | 1.57 | 1.57 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $16.1M | $16.1M | $-315.5M | $191.8M | $30.9M |
| Returns | |||||
| ROE | -16.0% | -16.0% | 3.5% | 8.3% | 13.6% |
| Valuation | |||||
| P/E | — | — | 62.08 | 49.15 | 25.87 |
| EV/EBITDA | — | — | 25.79 | 33.16 | 18.89 |
| P/B | 1.41 | 1.41 | 2.18 | 4.07 | 3.53 |
| Growth & Yield | |||||
| Revenue Growth | -17.4% | -17.4% | -12.1% | -8.8% | — |
| EPS Growth | -475.0% | -475.0% | -59.3% | -37.9% | — |
| Dividend Yield | 3.2% | 3.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-38.1%
Start / end P/E
n/dx → n/dx
EPS bridge
0.24 → -0.90
Residual
-41.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.